Biotech · Private company
XenoPort, Inc.
Track this companyFree. Adds XenoPort, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials130 recruiting or active
Pipeline programs31From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline31
- Arbaclofen placarbil 15 mg BIDPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Arbaclofen placarbil 30 mg BIDPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Arbaclofen placarbil 45 mg BIDPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- arbaclofen placarbil-Cohort 1Phase 2 · Gastroesophageal Reflux DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- arbaclofen placarbil-Cohort 2Phase 2 · Gastroesophageal Reflux DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- arbaclofen placarbil-Cohort 3Phase 2 · Gastroesophageal Reflux DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- arbaclofen placarbil-Cohort 4Phase 2 · Gastroesophageal Reflux DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Arbaclofen placarbil, 20 mgPhase 2 · Back PainClinicalTrials.gov · fetched Nov 12, 2026
- Arbaclofen placarbil, 30 mgPhase 2 · Back PainClinicalTrials.gov · fetched Nov 12, 2026
- Arbaclofen placarbil, 40 mgPhase 2 · Back PainClinicalTrials.gov · fetched Nov 12, 2026
- Carbidopa PillPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- PPIPhase 2 · Gastroesophageal Reflux DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Sinemet (comparator)Phase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Sinemet 25-100 Oral TabletPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR1, 10 mg BIDPhase 2 · Muscle SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR1, 20 mg BIDPhase 2 · Muscle SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR1, 30 mg BIDPhase 2 · Muscle SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR3, 20 mg QDPhase 2 · Gastroesophageal RefluxClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR3, 30 mg BIDPhase 2 · Gastroesophageal RefluxClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR3, 40 mg QDPhase 2 · Gastroesophageal RefluxClinicalTrials.gov · fetched Nov 12, 2026
- XP19986 SR3, 60 mg QDPhase 2 · Gastroesophageal RefluxClinicalTrials.gov · fetched Nov 12, 2026
- XP21279Phase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- XP21279 and carbidopa (experimental)Phase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GEn 1200mgPhase 1 · Restless Legs SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Gen 6000 mgPhase 1 · Restless Legs SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- HORIZANT 300 mgPhase 1 · RLSClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinPhase 1 · Restless Legs SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- GSK1838262 300 mgRestless Legs SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- GSK1838262 450 mgRestless Legs SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- GSK1838262 600 mgRestless Legs SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- HORIZANT 600 mgRLSClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials13
- An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSPHASE4 · UNKNOWN · started Feb 1, 2016ClinicalTrials.gov NCT02560766 · fetched Nov 12, 2026
- A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLSPHASE1 · WITHDRAWN · started Jan 1, 2016ClinicalTrials.gov NCT02633657 · fetched Nov 12, 2026
- An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLSPHASE4 · UNKNOWN · started Jan 1, 2016ClinicalTrials.gov NCT02633683 · fetched Nov 12, 2026
- A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type PsoriasisPHASE2 · COMPLETED · started Jun 1, 2014ClinicalTrials.gov NCT02173301 · fetched Nov 12, 2026
- Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment StudyPHASE4 · COMPLETED · started Jun 1, 2012ClinicalTrials.gov NCT01668667 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy VolunteersPHASE1 · COMPLETED · started Jan 1, 2012ClinicalTrials.gov NCT01516372 · fetched Nov 12, 2026
- Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisPHASE3 · COMPLETED · started May 1, 2011ClinicalTrials.gov NCT01359566 · fetched Nov 12, 2026
- A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease SubjectsPHASE2 · COMPLETED · started Jul 1, 2010ClinicalTrials.gov NCT01171313 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)PHASE2 · COMPLETED · started Sep 1, 2009ClinicalTrials.gov NCT00978016 · fetched Nov 12, 2026
- An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsPHASE1_PHASE2 · COMPLETED · started May 1, 2009ClinicalTrials.gov NCT00914602 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back SpasmsPHASE2 · COMPLETED · started Dec 1, 2008ClinicalTrials.gov NCT00817986 · fetched Nov 12, 2026
- A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord InjuryPHASE2 · COMPLETED · started Dec 1, 2007ClinicalTrials.gov NCT00557973 · fetched Nov 12, 2026
- An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERDPHASE2 · COMPLETED · started Nov 1, 2007ClinicalTrials.gov NCT00557401 · fetched Nov 12, 2026